Dr. Sweis is a physician-scientist working to identify and circumvent mechanisms of resistance to cancer immunotherapies. His laboratory research is focused on modulating the tumor microenvironment to facilitate anti-tumor immune responses, using mouse models of bladder and skin cancers. In the clinic, he uses his expertise in developmental therapeutics and clinical pharmacology to investigate biomarkers and novel therapeutic strategies to improve immunotherapy efficacy in patients.
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer. Clin Cancer Res. 2024 Mar 27.
PMID: 38536082
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024; 15:1358019.
PMID: 38515743
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024 Apr; 42(2):179-184.
PMID: 38372949
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16.
PMID: 38394781
Bladder-Preserving Trimodality Therapy With Capecitabine.
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
PMID: 38228414
Melanoma and microbiota: Current understanding and future directions.
Melanoma and microbiota: Current understanding and future directions. Cancer Cell. 2024 01 08; 42(1):16-34.
PMID: 38157864
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms.
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms. Sci Rep. 2023 12 18; 13(1):22541.
PMID: 38110479
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2023 Dec 16.
PMID: 38105142
Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2023 06 13; 29(12):2336.
PMID: 37309603
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy. Curr Oncol Rep. 2023 03; 25(3):189-199.
PMID: 36705879